Daniel Busby
Stock Analyst at RBC Capital
(1.19)
# 3,348
Out of 4,820 analysts
6
Total ratings
50%
Success rate
-8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $16 → $4 | $0.49 | +716.66% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $22.92 | +91.97% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $4.74 | +5.60% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $186.06 | -27.44% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $16 → $4
Current: $0.49
Upside: +716.66%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $22.92
Upside: +91.97%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $4.74
Upside: +5.60%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $186.06
Upside: -27.44%